SCHEMBL15918320

SCHEMBL15918320

COc1cc2nccc(Oc3ccc(N(C(=O)C4(C(N)=O)CC4)c4ccc(F)cc4)cc3)c2cc1OCCCC(=O)NO

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 12/20 0.62
KDR P35968 6/20 0.62
AXL P30530 6/20 0.62
HDAC2 Q92769 3/20 0.62
HDAC8 Q9BY41 3/20 0.62
HDAC6 Q9UBN7 3/20 0.62
RET P07949 2/20 0.62
KIT P10721 2/20 0.62
FLT3 P36888 2/20 0.62
PDGFRB P09619 1/20 0.62
HDAC10 Q969S8 2/20 0.59
HDAC11 Q96DB2 2/20 0.59
MERTK Q12866 2/20 0.56
FLT1 P17948 2/20 0.56
AURKB Q96GD4 2/20 0.56
AURKA O14965 1/20 0.56
RIPK2 O43353 1/20 0.56
ABCB11 O95342 1/20 0.56
ABL1 P00519 1/20 0.56
EGFR P00533 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15918222 1.00 MET (0.62) METKDRAXLHDAC2HDAC8
SCHEMBL15918338 0.98 HDAC2 (0.62) METKDRAXLHDAC2HDAC8
SCHEMBL15918345 0.98 HDAC2 (0.62) METKDRAXLHDAC2HDAC8
SCHEMBL15918364 0.97 HDAC2 (0.63) METKDRAXLHDAC2HDAC8
SCHEMBL15918240 0.97 HDAC2 (0.63) METKDRAXLHDAC2HDAC8
SCHEMBL15917759 0.97 HDAC2 (0.63) METKDRAXLHDAC2HDAC8
SCHEMBL15917251 0.97 HDAC2 (0.63) METKDRAXLHDAC2HDAC8
SCHEMBL15917971 0.96 MET (0.57) METKDRAXLHDAC2HDAC8
SCHEMBL15918227 0.96 MET (0.57) METKDRAXLHDAC2HDAC8
SCHEMBL15916806 0.94 MET (0.55) METKDRAXLHDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2769976-B1 HYDROXAMIC ACID COMPOUND CONTAINING QUINOLYL AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THIS COMPOUND AND USE THEREOF BEIJING KONRUNS PHARMACEUTICAL CO LTD (CN) 2017-08-02 EP claimed
US-9186318-B2 Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof BEIJING KONRUNS PHARMACEUTICAL CO., LTD (CN) 2015-11-17 US claimed
EP-2769976-A1 HYDROXAMIC ACID COMPOUND CONTAINING QUINOLYL AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THIS COMPOUND AND USE THEREOF Beijing Konruns Pharmaceutical Co., Ltd. (CN) 2014-08-27 EP claimed
US-20140221425-A1 Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) 2014-08-07 US claimed
EP-2769976-B1 HYDROXAMIC ACID COMPOUND CONTAINING QUINOLYL AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THIS COMPOUND AND USE THEREOF BEIJING KONRUNS PHARMACEUTICAL CO LTD (CN) 2017-08-02 EP disclosed
US-9186318-B2 Quinolyl-containing hydroxamic acid compound and preparation method thereof, and pharmaceutical composition containing this compound and use thereof BEIJING KONRUNS PHARMACEUTICAL CO., LTD (CN) 2015-11-17 US disclosed
EP-2769976-A1 HYDROXAMIC ACID COMPOUND CONTAINING QUINOLYL AND PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THIS COMPOUND AND USE THEREOF Beijing Konruns Pharmaceutical Co., Ltd. (CN) 2014-08-27 EP disclosed
US-20140221425-A1 Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof BEIJING KONRUNS PHARMACEUTICAL CO., LTD. (CN) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221425-A1 Quinolyl-containing Hydroxamic Acid Compound and Preparation Method Thereof, and Pharmaceutical Composition Containing This Compound and Use Thereof HDAC5, HDAC1, HDAC7 MET 1782/4885KDR 3893/4885AXL 2018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.